Vision correction surgery trial to study both eyes
This article was originally published in Clinica
Executive Summary
US vision correction company Refractec is to begin treating both eyes of patients on the same day with its conductive keratoplasty (CKT) technique as part of a modified clinical trial of hyperopia correction. The US FDA approved the change to the Phase III trial based on hyperopic stability data during a one to nine month follow-up, which were equal to or better than that of competitors in the field, according to the Irvine, California-based company.